You have free access to this content

Appendices

  1. John Kelly

Published Online: 13 NOV 2009

DOI: 10.1002/9780470682920.app1

Principles of CNS Drug Development: From Test Tube to Patient

Principles of CNS Drug Development: From Test Tube to Patient

How to Cite

Kelly, J. (2010) Appendices, in Principles of CNS Drug Development: From Test Tube to Patient, John Wiley & Sons, Ltd, Chichester, UK. doi: 10.1002/9780470682920.app1

Author Information

  1. Department of Pharmacology and Therapeutics, National University of Ireland, Galway, Ireland

Publication History

  1. Published Online: 13 NOV 2009
  2. Published Print: 8 JAN 2010

ISBN Information

Print ISBN: 9780470519790

Online ISBN: 9780470682920

SEARCH

Summary

This appendix contains sections titled:

  • Appendix 1A A selection of drugs currently under development for the treatment of depression: single mechanism of action

  • Appendix 1B A selection of drugs currently under development for the treatment of depression: more than one mechanism of action

  • Appendix 1C Currently marketed drugs being examined for the treatment of depression

  • Appendix 2A A selection of drugs currently under development for the treatment of schizophrenia: single mechanism of action

  • Appendix 2B A selection of drugs currently under development for the treatment of schizophrenia: more than one mechanism of action

  • Appendix 2C Currently marketed drugs being examined for the treatment of schizophrenia

  • Appendix 3A A selection of drugs currently under development for the treatment of Alzheimer's disease: single mechanism of action

  • Appendix 3B A selection of drugs currently under development for the treatment of Alzheimer's disease: more than one mechanism of action

  • Appendix 3C Currently marketed drugs being examined for the treatment of Alzheimer's disease

  • Appendix 4A A selection of drugs currently under development for the treatment of Parkinson's disease: single mechanism of action

  • Appendix 4B A selection of drugs currently under development for the treatment of Parkinson's Disease: more than one mechanism of action